Therapy of syndrome malin

Area of Science:

• Pharmacology
• Neuroscience
• Critical Care Medicine

Background:

• Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening adverse reaction to antipsychotic medications.
• Characterized by a distinct triad of symptoms: extrapyramidal signs, hyperthermia, and autonomic instability.
• Historically associated with older antipsychotics like haloperidol, but can occur with any neuroleptic agent.

Purpose of the Study:

• To review the clinical presentation and pathophysiology of Neuroleptic Malignant Syndrome (NMS).
• To discuss the limitations of traditional supportive care for NMS.
• To explore the emerging therapeutic roles of dopaminergic agonists and dantrolene in NMS management.

Main Methods:

• Literature review of reported cases and treatment strategies for Neuroleptic Malignant Syndrome.
• Analysis of proposed etiological mechanisms, including dopaminergic blockade and similarities to malignant hyperthermia.
• Evaluation of clinical evidence supporting the efficacy of bromocriptine, amantadine, and dantrolene.

Main Results:

• Neuroleptic Malignant Syndrome presents with severe symptoms including rigidity, fever, and autonomic dysfunction, often requiring intensive care.
• NMS is not strictly dose-dependent and can manifest unpredictably during neuroleptic treatment.
• Bromocriptine, amantadine, and dantrolene have shown promise in alleviating NMS symptoms, suggesting specific therapeutic targets.

Conclusions:

• Traditional supportive care for NMS is often insufficient.
• Pharmacological interventions targeting dopaminergic pathways (bromocriptine, amantadine) or muscle rigidity (dantrolene) represent significant advancements.
• These newer agents offer more specific and potentially life-saving treatments for Neuroleptic Malignant Syndrome.